These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 27432635

  • 21. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention.
    Sigle JP, Thierbach J, Infanti L, Muriset M, Hunziker G, Chassot K, Niederhauser C, Gowland P, Holbro A, Sunic K, Buser A, Fontana S.
    Vox Sang; 2013 Oct; 105(3):244-52. PubMed ID: 23773018
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Apheresis technology correlates with bacterial contamination of platelets and reported septic transfusion reactions.
    Eder AF, Dy BA, DeMerse B, Wagner SJ, Stramer SL, O'Neill EM, Herron RM.
    Transfusion; 2017 Dec; 57(12):2969-2976. PubMed ID: 28880363
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A critical comparison of platelet preparation methods.
    Vassallo RR, Murphy S.
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [Abstract] [Full Text] [Related]

  • 26. [Transfusion-transmitted bacterial infection of a apheresis platelet concentrate with Streptococcus gallolyticus: Analysis of one case].
    Le Niger C, Dalbies F, Narbonne V, Hery-Arnaud G, Virmaux M, Léostic C, Hervé F, Liétard C.
    Transfus Clin Biol; 2014 Jun; 21(3):107-10. PubMed ID: 24934685
    [Abstract] [Full Text] [Related]

  • 27. Clinical Indications and Adverse Reactions of Platelet Apheresis.
    Amanat ST, Shakoor HA, Raza M, Khan N, Rauf A.
    J Coll Physicians Surg Pak; 2015 Jun; 25(6):403-6. PubMed ID: 26100990
    [Abstract] [Full Text] [Related]

  • 28. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H, Seifried E.
    Vox Sang; 2010 Jul 01; 99(1):1-15. PubMed ID: 20059760
    [Abstract] [Full Text] [Related]

  • 29. The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil.
    Blatyta PF, Custer B, Liu J, Mendrone-Junior A, Wright DJ, Leão SC, Lopes MI, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, NHLBI Retrovirus Epidemiology Donor Study-II (REDSII), International Component.
    Transfus Apher Sci; 2013 Feb 01; 48(1):15-20. PubMed ID: 22985535
    [Abstract] [Full Text] [Related]

  • 30. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006).
    Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ, American Red Cross Regional Blood Centers.
    Transfusion; 2007 Jul 01; 47(7):1134-42. PubMed ID: 17581147
    [Abstract] [Full Text] [Related]

  • 31. High-yield platelet concentrates attainable by continuous quality improvement reduce platelet transfusion cost and donor exposure.
    Kelley DL, Fegan RL, Ng AT, Kennedy MK, Blanda E, Chambers LA, Kennedy MS, Lasky LC.
    Transfusion; 1997 May 01; 37(5):482-6. PubMed ID: 9149771
    [Abstract] [Full Text] [Related]

  • 32. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J, Humpe A, Simson G, Köhler M.
    Vox Sang; 1998 May 01; 74(3):182-8. PubMed ID: 9595646
    [Abstract] [Full Text] [Related]

  • 33. Platelet Yield and Some Donor-Related Predictors in a Single Donor Apheresis: Report from a Nigerian Tertiary Hospital.
    Ugwu GC, Okoye HC, Nnachi OC, Nwani E, Nnachi OA, Ezenwenyi IP, Ugwu NI, Okoye AE.
    West Afr J Med; 2022 Dec 29; 39(12):1280-1284. PubMed ID: 36583368
    [Abstract] [Full Text] [Related]

  • 34. Risk-reduction strategies for platelet transfusion in the United States.
    Vamvakas EC.
    ScientificWorldJournal; 2011 Mar 07; 11():624-40. PubMed ID: 21403979
    [Abstract] [Full Text] [Related]

  • 35. Interventions to reduce platelet prophylactic transfusions in patients with hypoproliferative thrombocytopenia: providing patients with the full benefit.
    Vamvakas EC, Hitzler WE.
    Clin Lab; 2013 Mar 07; 59(5-6):459-64. PubMed ID: 23865342
    [Abstract] [Full Text] [Related]

  • 36. Postdonation platelet counts are safe when collecting platelets with the Trima Accel using a postdonation platelet count target of > or =50,000 platelets/microL.
    Alex J, Roberts B, Raife T.
    J Clin Apher; 2009 Mar 07; 24(5):215-7. PubMed ID: 19816960
    [Abstract] [Full Text] [Related]

  • 37. The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages.
    Stubbs JR, Homer MJ, Silverman T, Cap AP.
    Transfusion; 2021 Jan 07; 61(1):303-312. PubMed ID: 33098328
    [Abstract] [Full Text] [Related]

  • 38. Febrile reactions after platelet transfusion: the effect of single versus multiple donors.
    Chambers LA, Kruskall MS, Pacini DG, Donovan LM.
    Transfusion; 1990 Jan 07; 30(3):219-21. PubMed ID: 1967118
    [Abstract] [Full Text] [Related]

  • 39. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN.
    Transfus Apher Sci; 2009 Oct 07; 41(2):115-9. PubMed ID: 19716340
    [Abstract] [Full Text] [Related]

  • 40. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers.
    Arnold DM, Heddle NM, Kulczycky M, Carruthers J, Sigouin C, Blajchman MA.
    Transfusion; 2006 Feb 07; 46(2):257-64. PubMed ID: 16441604
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.